(Q31882653)

4 July 2017

title

Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist (English)

1 reference

4 July 2017

Baurand A

1

1 reference

4 July 2017

Raboisson P

2

1 reference

4 July 2017

Freund M

3

1 reference

4 July 2017

Léon C

4

1 reference

4 July 2017

Cazenave JP

5

1 reference

4 July 2017

Bourguignon JJ

6

1 reference

4 July 2017

Gachet C

7

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

European Journal of Pharmacology

4 July 2017

published in

1 reference

4 July 2017

volume

412

1 reference

4 July 2017

issue

3

1 reference

4 July 2017

page(s)

213-221

1 reference

Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

ADP receptors and clinical bleeding disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

LIGAND: A versatile computerized approach for characterization of ligand-binding systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2900733-6

10.1016/S0014-2999(01)00733-6

7 January 2021

Identifiers

DOI

1 reference

4 July 2017

1 reference